Shield Therapeutics plc (FRA:1JS)

Shield Therapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 26, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	117	26	60	21	114	83
Market Cap Growth	372.58%	-57.71%	192.87%	-81.97%	37.20%	-66.33%
Enterprise Value	131	37	53	18	87	76
Last Close Price	0.12	0.03	0.07	0.07	0.45	0.64
PS Ratio	3.32	0.82	5.10	4.01	63.24	7.19
PB Ratio	-9.26	-20.07	4.44	3.37	2.36	2.47
P/TBV Ratio	-	-	4.82	4.15	4.11	6.53
P/FCF Ratio	27.24	-	-	-	-	-
P/OCF Ratio	27.23	-	-	-	-	-
EV/Sales Ratio	3.79	1.19	4.50	3.48	48.36	6.56
EV/EBITDA Ratio	-	-	-	-	-	2840.59
EV/FCF Ratio	30.37	-	-	-	-	-
Debt / Equity Ratio	-1.82	-20.02	1.35	1.04	0.00	0.00
Debt / EBITDA Ratio	-	-	-	-	-	1.17
Debt / FCF Ratio	5.35	-	-	-	-	-
Asset Turnover	0.76	0.61	0.35	0.14	0.04	0.30
Inventory Turnover	3.98	3.89	3.65	1.63	0.65	1.16
Quick Ratio	0.69	0.90	1.83	0.62	3.73	1.60
Current Ratio	0.83	1.16	2.28	0.95	4.64	2.32
Return on Equity (ROE)	-	-396.36%	-308.60%	-179.19%	-55.46%	-8.43%
Return on Assets (ROA)	-16.77%	-26.90%	-51.93%	-49.37%	-32.97%	-3.91%
Return on Capital (ROIC)	-55.83%	-47.39%	-80.56%	-63.24%	-35.65%	-4.31%
Return on Capital Employed (ROCE)	-120.80%	-92.00%	-89.40%	-229.50%	-49.90%	-7.10%
Earnings Yield	-15.44%	-102.83%	-49.88%	-225.97%	-20.48%	-3.52%
FCF Yield	3.67%	-25.74%	-55.98%	-102.82%	-19.40%	-1.87%
Buyback Yield / Dilution	-19.74%	-8.33%	-209.85%	-14.08%	-74.36%	-0.21%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.